Cargando…
Volatile Isoflurane in Critically Ill Coronavirus Disease 2019 Patients—A Case Series and Systematic Review
OBJECTIVES: The ongoing coronavirus pandemic is challenging, especially in severely affected patients who require intubation and sedation. Although the potential benefits of sedation with volatile anesthetics in coronavirus disease 2019 patients are currently being discussed, the use of isoflurane i...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7587445/ https://www.ncbi.nlm.nih.gov/pubmed/33134946 http://dx.doi.org/10.1097/CCE.0000000000000256 |
_version_ | 1783600176232923136 |
---|---|
author | Flinspach, Armin Niklas Zacharowski, Kai Ioanna, Deligiannis Adam, Elisabeth Hannah |
author_facet | Flinspach, Armin Niklas Zacharowski, Kai Ioanna, Deligiannis Adam, Elisabeth Hannah |
author_sort | Flinspach, Armin Niklas |
collection | PubMed |
description | OBJECTIVES: The ongoing coronavirus pandemic is challenging, especially in severely affected patients who require intubation and sedation. Although the potential benefits of sedation with volatile anesthetics in coronavirus disease 2019 patients are currently being discussed, the use of isoflurane in patients with coronavirus disease 2019–induced acute respiratory distress syndrome has not yet been reported. DESIGN: We performed a retrospective analysis of critically ill patients with hypoxemic respiratory failure requiring mechanical ventilation. SETTING: The study was conducted with patients admitted between April 4 and May 15, 2020 to our ICU. PATIENTS: We included five patients who were previously diagnosed with severe acute respiratory syndrome coronavirus 2 infection. INTERVENTION: Even with high doses of several IV sedatives, the targeted level of sedation could not be achieved. Therefore, the sedation regimen was switched to inhalational isoflurane. Clinical data were recorded using a patient data management system. We recorded demographical data, laboratory results, ventilation variables, sedative dosages, sedation level, prone positioning, duration of volatile sedation and outcomes. MEASUREMENTS & MAIN RESULTS: Mean age (four men, one women) was 53.0 (± 12.7) years. The mean duration of isoflurane sedation was 103.2 (± 66.2) hours. Our data demonstrate a substantial improvement in the oxygenation ratio when using isoflurane sedation. Deep sedation as assessed by the Richmond Agitation and Sedation Scale was rapidly and closely controlled in all patients, and the subsequent discontinuation of IV sedation was possible within the first 30 minutes. No adverse events were detected. CONCLUSIONS: Our findings demonstrate the feasibility of isoflurane sedation in five patients suffering from severe coronavirus disease 2019 infection. Volatile isoflurane was able to achieve the required deep sedation and reduced the need for IV sedation. |
format | Online Article Text |
id | pubmed-7587445 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-75874452020-10-29 Volatile Isoflurane in Critically Ill Coronavirus Disease 2019 Patients—A Case Series and Systematic Review Flinspach, Armin Niklas Zacharowski, Kai Ioanna, Deligiannis Adam, Elisabeth Hannah Crit Care Explor Original Clinical Report OBJECTIVES: The ongoing coronavirus pandemic is challenging, especially in severely affected patients who require intubation and sedation. Although the potential benefits of sedation with volatile anesthetics in coronavirus disease 2019 patients are currently being discussed, the use of isoflurane in patients with coronavirus disease 2019–induced acute respiratory distress syndrome has not yet been reported. DESIGN: We performed a retrospective analysis of critically ill patients with hypoxemic respiratory failure requiring mechanical ventilation. SETTING: The study was conducted with patients admitted between April 4 and May 15, 2020 to our ICU. PATIENTS: We included five patients who were previously diagnosed with severe acute respiratory syndrome coronavirus 2 infection. INTERVENTION: Even with high doses of several IV sedatives, the targeted level of sedation could not be achieved. Therefore, the sedation regimen was switched to inhalational isoflurane. Clinical data were recorded using a patient data management system. We recorded demographical data, laboratory results, ventilation variables, sedative dosages, sedation level, prone positioning, duration of volatile sedation and outcomes. MEASUREMENTS & MAIN RESULTS: Mean age (four men, one women) was 53.0 (± 12.7) years. The mean duration of isoflurane sedation was 103.2 (± 66.2) hours. Our data demonstrate a substantial improvement in the oxygenation ratio when using isoflurane sedation. Deep sedation as assessed by the Richmond Agitation and Sedation Scale was rapidly and closely controlled in all patients, and the subsequent discontinuation of IV sedation was possible within the first 30 minutes. No adverse events were detected. CONCLUSIONS: Our findings demonstrate the feasibility of isoflurane sedation in five patients suffering from severe coronavirus disease 2019 infection. Volatile isoflurane was able to achieve the required deep sedation and reduced the need for IV sedation. Lippincott Williams & Wilkins 2020-10-21 /pmc/articles/PMC7587445/ /pubmed/33134946 http://dx.doi.org/10.1097/CCE.0000000000000256 Text en Copyright © 2020 The Authors. Published by Wolters Kluwer Health, Inc. on behalf of the Society of Critical Care Medicine. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (http://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. This article is made available via the PMC Open Access Subset for unrestricted re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the COVID-19 pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections. |
spellingShingle | Original Clinical Report Flinspach, Armin Niklas Zacharowski, Kai Ioanna, Deligiannis Adam, Elisabeth Hannah Volatile Isoflurane in Critically Ill Coronavirus Disease 2019 Patients—A Case Series and Systematic Review |
title | Volatile Isoflurane in Critically Ill Coronavirus Disease 2019 Patients—A Case Series and Systematic Review |
title_full | Volatile Isoflurane in Critically Ill Coronavirus Disease 2019 Patients—A Case Series and Systematic Review |
title_fullStr | Volatile Isoflurane in Critically Ill Coronavirus Disease 2019 Patients—A Case Series and Systematic Review |
title_full_unstemmed | Volatile Isoflurane in Critically Ill Coronavirus Disease 2019 Patients—A Case Series and Systematic Review |
title_short | Volatile Isoflurane in Critically Ill Coronavirus Disease 2019 Patients—A Case Series and Systematic Review |
title_sort | volatile isoflurane in critically ill coronavirus disease 2019 patients—a case series and systematic review |
topic | Original Clinical Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7587445/ https://www.ncbi.nlm.nih.gov/pubmed/33134946 http://dx.doi.org/10.1097/CCE.0000000000000256 |
work_keys_str_mv | AT flinspacharminniklas volatileisofluraneincriticallyillcoronavirusdisease2019patientsacaseseriesandsystematicreview AT zacharowskikai volatileisofluraneincriticallyillcoronavirusdisease2019patientsacaseseriesandsystematicreview AT ioannadeligiannis volatileisofluraneincriticallyillcoronavirusdisease2019patientsacaseseriesandsystematicreview AT adamelisabethhannah volatileisofluraneincriticallyillcoronavirusdisease2019patientsacaseseriesandsystematicreview |